IMPAX Laboratories, Inc. announced that Alza Corporation and McNeil-PPC, Inc. have filed a complaint against the Company in the United States District Court for the District of Delaware, alleging patent infringement related to IMPAX's filing for a generic version of Concerta(r). The plaintiffs have not served IMPAX with the complaint. IMPAX has submitted its filing with the U.S. Food and Drug Administration (FDA) under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions of Concerta(r) tablets do not infringe the listed patents or that the listed patents are invalid or unenforceable.

Is there a date that the generic will be on the market?